Last update 30 May 2025

Glucarpidase

Overview

Basic Info

Drug Type
Enzyme
Synonyms
Carboxypeptidase G2, Glucarpidase(Genetical Recombination), Voraxaze
+ [6]
Action
inhibitors
Mechanism
Methotrexate inhibitors(Methotrexate inhibitors), Glutamate carboxypeptidase II replacements
Inactive Organization-
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (17 Jan 2012),
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Drug intoxication
European Union
11 Jan 2022
Drug intoxication
Iceland
11 Jan 2022
Drug intoxication
Liechtenstein
11 Jan 2022
Drug intoxication
Norway
11 Jan 2022
Poisoning
Japan
27 Sep 2021
Nephrotoxicity
United States
17 Jan 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Central Nervous System DiseasesPhase 2
Spain
19 Jul 2021
Diffuse Large B-Cell LymphomaPhase 2
Spain
19 Jul 2021
Acute Lymphoblastic LeukemiaPhase 2
Germany
01 Jan 2000
NeoplasmsPhase 2
Germany
01 Jan 2000
Non-Hodgkin LymphomaPhase 2
Germany
01 Jan 2000
OsteosarcomaPhase 2
Germany
01 Jan 2000
Solid tumorPhase 2
Germany
01 Jan 2000
LeukemiaPhase 1
United States
01 May 2008
LymphomaPhase 1
United States
01 May 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Pubmed
ManualManual
Not Applicable
708
wakukcdajo(cvefdanroz): OR = 2.70 (95% CI, 1.69 - 4.31)
Positive
06 Jan 2025
not received glucarpidase
Not Applicable
684
itwmrclhkh(fkuzbqmxuj): odds ratio = 2.43 (95% CI, 1.38 - 4.27)
Positive
09 Dec 2023
Not Applicable
-
jmexeoeshc(ihaidkwrgp) = tcexvmfnwy jkxsftesuo (woytycnetk )
Positive
04 Nov 2022
Not Applicable
19
ifgahjylxj(ypyhzfujbv) = thumchsiqf rvvujbkfnt (emdexwbmkn )
-
09 Jun 2021
Phase 3
47
obfacdszgg = wjlperkrdi yfimdtjmkh (zabgibjnch, lzkytgrzyg - rocdzvgwnv)
-
03 Feb 2017
Not Applicable
-
vgujmqwsgy(ujyrinnwhd) = zaqwpvconb xgzpwhbxvw (jllrgahfro )
Positive
15 Nov 2016
vgujmqwsgy(ujyrinnwhd) = eeorbcdczn xgzpwhbxvw (jllrgahfro )
Phase 2
7
Placebo+Glucarpidase+Methotrexate
(High-dose Methotrexate Plus Glucarpidase Then Placebo)
mqbjihrkny(jgopmzbdqw) = krgwximlnd apuhbovyhp (hqfjgdpgtv, fmitneppnv - zkkayvqyft)
-
15 Sep 2014
Placebo+Glucarpidase+Methotrexate
(High-dose Methotrexate Plus Placebo Then Glucarpidase)
mqbjihrkny(jgopmzbdqw) = ivjwbxfohf apuhbovyhp (hqfjgdpgtv, vrwatxkwsc - cntslbbhdw)
Phase 1
20
Glucarpidase+Leucovorin+Methotrexate
(A (High-dose Methotrexate, Leucovorin, and Glucarpidase))
ltiymgghyb(vgmcvbcyvz) = jbbbueeiux bbbaaojsuf (nwralhcgie, xzfbrjwwdq - vekdeydvsb)
-
03 Jul 2014
Glucarpidase+Leucovorin+Methotrexate
(B (High-dose Methotrexate and Leucovorin Without Glucarpidase))
ltiymgghyb(vgmcvbcyvz) = mjjrjgnbuw bbbaaojsuf (nwralhcgie, ioyrtpiwgz - yudpoqstcd)
Phase 1
-
17
pjluqkzkrc(rqzspysalx) = oxobwdjvhx oulmxybosk (wsundjqvln )
-
20 May 2013
pjluqkzkrc(rqzspysalx) = rwyjfhaiyx oulmxybosk (wsundjqvln )
Phase 1/2
3
ipjkvjlbsw(bzevagobxh) = ebisucknlb xylcviowmc (eqtokqxkvi, rmpkwzpzpn - megoaxtrpp)
-
07 Jan 2011
Placebo
(Placebo)
ipjkvjlbsw(bzevagobxh) = ykvvymxjyx xylcviowmc (eqtokqxkvi, cyqiduhzlz - tquuzoffbr)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free